Analysts Offer Predictions for Repligen FY2025 Earnings

Repligen Co. (NASDAQ:RGEN) – Investment analysts at William Blair dropped their FY2025 earnings per share estimates for Repligen in a research note issued to investors on Wednesday, December 11th. William Blair analyst M. Larew now anticipates that the biotechnology company will earn $1.79 per share for the year, down from their previous forecast of $2.16. The consensus estimate for Repligen’s current full-year earnings is $1.54 per share.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the business posted $0.23 EPS. The business’s quarterly revenue was up 9.7% on a year-over-year basis.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Performance

NASDAQ RGEN opened at $156.41 on Monday. The firm has a market cap of $8.76 billion, a price-to-earnings ratio of -422.73, a PEG ratio of 4.64 and a beta of 0.96. The company has a 50-day simple moving average of $142.66 and a two-hundred day simple moving average of $141.59. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13.

Institutional Investors Weigh In On Repligen

Several institutional investors and hedge funds have recently modified their holdings of the stock. Andra AP fonden bought a new position in Repligen in the second quarter worth about $25,000. International Assets Investment Management LLC bought a new position in shares of Repligen in the 2nd quarter worth approximately $33,000. UMB Bank n.a. lifted its stake in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. lifted its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the period. Finally, Resources Management Corp CT ADV bought a new stake in shares of Repligen during the third quarter valued at approximately $37,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.